Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Tables)

v3.21.2
SEGMENT INFORMATION (Tables)
6 Months Ended
Jun. 30, 2021
Segment Reporting [Abstract]  
Schedule of segment reporting information
The following table presents information by reportable operating segment for the three and six months ended June 30, 2021 and 2020 (in thousands):
Consumer Products
Segment
Specialty Pharmaceutical Segment Consolidated Totals
Three months ended June 30, 2021:
Product sales, net $ 5,128  $ —  $ 5,128 
Gross profit $ 2,290  $ —  $ 2,290 
Research and development expense 126  99  225 
Selling, general and administrative expense 5,565  10  5,575 
Operating loss $ (3,401) $ (109) $ (3,510)
Three months ended June 30, 2020:
Product sales, net $ 5,396  $ —  $ 5,396 
Gross profit $ 2,322  $ —  $ 2,322 
Research and development expense 152  594  746 
Selling, general and administrative expense 6,180  53  6,233 
Operating loss $ (4,010) $ (647) $ (4,657)

Consumer Products
Segment
Specialty Pharmaceutical Segment Consolidated Totals
Six months ended June 30, 2021:
Product sales, net $ 9,972  $ —  $ 9,972 
Gross profit 4,648  —  4,648 
Research and development expense 254  157  411 
Selling, general and administrative expense 10,835  25  10,860 
Operating loss $ (6,441) $ (182) $ (6,623)
Six months ended June 30, 2020:
Product sales, net $ 13,666  $ —  $ 13,666 
Gross profit 6,330  —  $ 6,330 
Research and development expense 457  1,798  2,255 
Selling, general and administrative expense 13,990  62  $ 14,052 
Operating loss $ (8,117) $ (1,860) $ (9,977)